...
机译:选择性CDK7共价抑制剂的发展揭示了主要细胞循环表型
Department of Cancer Biology Dana-Farber Cancer Institute;
Department of Cancer Biology Dana-Farber Cancer Institute;
Department of Cancer Biology Dana-Farber Cancer Institute;
Department of Molecular &
Human Genetics Baylor College of Medicine;
Departments of Biochemistry and Radiation Oncology The University of Texas Southwestern Medical Center at Dallas;
Laboratory of Systems Pharmacology Harvard Medical School;
Department of Molecular &
Human Genetics Baylor College of Medicine;
Department of Cancer Biology Dana-Farber Cancer Institute;
Department of Cancer Biology Dana-Farber Cancer Institute;
Institute of Structural Biology University of Bonn;
Institute of Structural Biology University of Bonn;
Chemical Kinomics Research Center Korea Institute of Science and Technology (KIST);
Department of Cancer Biology Dana-Farber Cancer Institute;
Laboratory of Systems Pharmacology Harvard Medical School;
Departments of Biochemistry and Radiation Oncology The University of Texas Southwestern Medical Center at Dallas;
Therapeutic Innovation Center (THINC@BCM) Baylor College of Medicine;
Department of Cancer Biology Dana-Farber Cancer Institute;
Department of Cancer Biology Dana-Farber Cancer Institute;
transcription; gene expression; cell cycle; drug discovery; cancer; small-molecule inhibitor;
机译:选择性CDK7共价抑制剂的发展揭示了主要细胞循环表型
机译:SY-1365的发现与表征,CDK7的选择性,共价抑制剂
机译:新型共价抑制剂对CDK7的强效和选择性抑制
机译:共价抑制蛋白质 - 蛋白质相互作用(1):基于N-酰基-N-烷基磺酰胺(NASA)弹头的共价抑制剂的发育
机译:基于表型的具有构象特异性抑制剂的筛选显示P38γ和δ作为肝细胞癌的治疗靶标。
机译:选择性共价Janus激酶3抑制剂的开发
机译:SY-1365的发现与表征,CDK7的选择性,共价抑制剂